文献速递糖尿病

美国各州及哥伦比亚特区确诊糖尿病的经济成本:2021年

Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021.
PubMed 文献 · Diabetes Care · 2025-01-01

该研究采用归因分值法估算美国各州2021年确诊糖尿病的直接医疗成本与间接生产力损失,并评估2013至2021年支出变化。2013至2021年总成本中位数增长33%,医疗补助支付成本增幅最高(中位数153%)。

要点

  • 2013至2021年总成本中位数增长33%(范围16%至68%),医疗补助支付成本中位数增长153%(范围41%至483%)。

核心结论

  • 确诊糖尿病的州级经济成本巨大,且在过去十年间有所增加,各州成本及其增长幅度差异很大;这些发现可能有助于州政策制定者制定循证公共卫生干预措施,以预防和控制各自州的糖尿病患病率。

研究设计与样本

  • 采用归因分值法,使用2021年州健康支出账户、2021年行为危险因素监测系统及2018至2019年联邦医疗保险和医疗补助服务中心最小数据集估算确诊糖尿病的直接医疗成本。
  • 使用2016至2021年全国健康访谈调查和2021年疾病控制与预防中心死亡率数据估算糖尿病归因的发病和死亡生产力损失;成本均调整为2021年美元。

主要发现

  • 2013至2021年总成本中位数增长33%(范围16%至68%),医疗成本总体增长50%(范围33%至79%),糖尿病患者人均医疗成本增长27%(范围15%至41%)。
  • 2013至2021年医疗补助支付的成本增幅最高(中位数153%;范围41%至483%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update state-specific estimates of diabetes-attributable costs in the U.S. and assess changes in spending from 2013 to 2021. RESEARCH DESIGN AND METHODS: We used an attributable fraction approach to estimate direct medical costs of diagnosed diabetes using the 2021 State Health Expenditure Accounts, the 2021 Behavioral Risk Factor Surveillance System, and the Centers for Medicare and Medicaid Services 2018-2019 Minimum Data Set. We estimated diabetes-attributable productivity losses from morbidity and mortality using the 2016-2021 National Health Interview Survey and the 2021 mortality data from the Centers for Disease Control and Prevention. Costs were adjusted to 2021 U.S. dollars. RESULTS: Total diabetes-attributable cost in 2021 was $640 billion ($335 billion in direct medical costs and $305 billion in indirect costs). The median state-level total diabetes-attributable cost was $8.2 billion (range $842 million to $81 billion). The median state-level per-person cost was $21,082, ranging from $17,452 to $37,090. Total diabetes-attributable cost increased by a median of 33% between 2013 and 2021, ranging from 16% to 68% across states. Medical costs increased by 50% overall (range 33-79%) and by 27% (range 15-41%) for per person with diabetes. Costs paid by Medicaid experienced the highest increase between 2013 and 2021 (median 153%; range 41-483%). CONCLUSIONS: State economic costs of diagnosed diabetes are substantial and increased over the last decade. These costs and their growth vary considerably across states. These findings may help state policymakers in developing evidenced-based public health interventions in their respective states to prevent and control the prevalence of diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Khavjou OA, Sun M, D'Angelo SR, et al. Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021. Diabetes Care. 2025. PMID: 39121032. doi:10.2337/dc24-0832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。